Journal of Clinical Oncology
Articles in this Issue
Explainable AI to predict molecular classes of renal cell carcinoma from digital pathology images.
4556 Background: There is an unmet need to develop rapidly deployable and reliable biomarkers to guide treatment decisions...
Clinical outcomes with 14- vs 28-day monitoring after CAR-T therapy.
e13590 Background: The US Food and Drug Administration recently eliminated the Risk Evaluation and Mitigation Strategies (...
Assessing the long-term impact of a public cancer screening program in Brazil: Ten years of experience.
e22505 Background: Cancer represents a major global health burden, with profound impacts on public health, society, and he...
Utidelone in heavily pretreated metastatic castration-resistant prostate cancer progressing after docetaxel and novel hormonal agents: Results of a completed phase II trial.
5059 Background: Patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after both doce...
Safety and efficacy of intratumoral (IT) ruxotemitide (LTX 315) in combination with pembrolizumab in patients with unresectable advanced melanoma or triple-negative breast cancer (TNBC).
2602 Background: Advanced unresectable cutaneous melanoma or TNBC are associated with poor prognosis and limited treatment...
Worst-case scenarios, triggers, and coping strategies among head and neck cancer caregivers.
e18097 Background: Head and neck cancers (HNCs) place a heavy burden on patients and informal caregivers (e.g., family, fr...
Real-world data on CLDN18.2 expression in gastric and gastroesophageal cancer patients.
e16038 Background: Gastric cancer (GC) and gastroesophageal junction cancer (GEJC) are highly lethal malignancies that are...
Impact of remote symptom monitoring on acute care utilization in phase I cancer patients: Secondary analysis of a randomized clinical trial.
1505 Background: Patients with advanced cancer undergoing Phase I therapies often experience high symptom burden and compl...
MSNPseq: An NGS-based assay for chimerism detection and risk assessment in allogeneic HSCT.
6557 Background: Chimerism (CHIM) analysis assesses the ratio of donor to recipient hematopoietic cells, confirming engraf...
HER2-positive central nervous system (CNS) surveillance: A study of the feasibility of randomizing women and men with HER2-positive metastatic breast cancer to CNS surveillance versus no surveillance.
TPS1146 Background: Breast cancer (BC) is the second most common primary tumour to metastasise to the brain (Aragon-Ching,...
SARS-CoV-2–associated Epstein–Barr virus reactivation and lymphomagenesis: A systematic review and meta-analysis.
e22586 Background: SARS-CoV-2 infection induces marked immune dysregulation, a biologic milieu permissive for reactivation...
Association of protein-energy malnutrition with mortality, resource utilization, and discharge disposition in pancreatic cancer: An analysis of the National Inpatient Sample (NIS).
e16364 Background: Pancreatic cancer is associated with substantial morbidity and mortality, with an overall 5-year surviv...
Disentangling <i>KEAP1</i> and <i>STK11</i> in <i>KRAS</i> -mutant ( <i>KRAS</i> m) non–small cell lung cancer (NSCLC) treated with immunotherapy.
e20583 Background: KEAP1 and STK11 are associated with poor re...
Psychological burden and burnout among regional healthcare providers communicating hereditary tumor findings: A multi-institutional communication skills training implementation study.
9020 Background: Psychological burden among healthcare providers in precision oncology affects workforce sustainability. I...
Multivariable analyses (MVAs) of overall survival (OS) in the phase 3 SUNMO, STARGLO, and POLARGO trials in relapsed/refractory large B-cell lymphoma (LBCL).
7093 Background: Phase 3 trials, notably SUNMO (NCT05171647), STARGLO (NCT04408638) and POLARGO (NCT04182204), have shown...
Non-D842V platelet-derived growth factor alpha (PDGFRA) mutant gastrointestinal stromal tumours (GISTs): A distinctive and heterogeneous subgroup— Experience from regional centre in United Kingdom.
e23517 Background: PDGFRA GISTs account for 10-15% of all gists and are almost exclusively gastric in origin. Around 50% o...
<i>ESR1</i> mutation longitudinal dynamics in RWD cohort of HR+/HER2− metastatic breast cancer patients treated with standard-of-care hormonal therapy.
3062 Background: ESR1 mutations ( ESR1 m) are known drivers of...
A phase 1/2 study of TSN1611, a highly selective oral KRAS G12D inhibitor, in solid tumors: Efficacy and safety in <i>KRAS</i> G12D–mutated NSCLC patients.
8516 Background: There remains an unmet clinical need for effective therapies targeting KRAS G12D mutation in patients (pt...
Biomarker landscape and survival outcomes in gastric adenocarcinoma: A Hispanic/Latino cohort from Colombia (2010–2024).
e16088 Background: Hispanic patients with gastric adenocarcinoma show distinct clinical patterns, including earlier onset,...
Whole-genome HRD phenotyping as a predictor of PARP inhibitor benefit in first-line maintenance high-grade serous ovarian cancer.
e17608 Background: Homologous recombination deficiency (HRD) in ovarian cancer identifies patients who may benefit from PA...
Exploratory plasma ctDNA genomic biomarkers identified by whole-exome sequencing and a novel bioinformatics pipeline in advanced driver-negative NSCLC.
e20540 Background: Immune checkpoint inhibitors (ICIs) have improved outcomes in advanced non-small-cell lung cancer (NSCL...
Immune priming with the EZH2 inhibitor tazemetostat in B-cell lymphomas receiving CAR T-cell therapy.
7035 Background: While chimeric antigen receptor (CAR) T cells have shown efficacy in B cell lymphomas, most patients (pts...
Sepsis severity and inpatient outcomes in metastatic cancer: A National Inpatient Sample study.
11197 Background: Sepsis is a major driver of acute decompensation and inpatient death in patients with cancer, with parti...
SHR-1826, a c-MET directed antibody-drug conjugate (ADC), in advanced solid tumors: Updates from a phase 1 study.
8525 Background: SHR-1826 is a novel ADC comprising a humanized IgG2 monoclonal antibody targeting c-MET, conjugated via a...
Belzutifan in docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Phase 1b/2 KEYNOTE-365 cohort J.
5058 Background: Hypoxia-inducible factor 2α (HIF-2α) is an established oncogenic driver, and HIF-2α expression in prostat...